Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Will Acquire China’s MeiRui
by Rick Mullin
December 13, 2010
| A version of this story appeared in
Volume 88, Issue 50
In a move to strengthen its position in China, GlaxoSmithKline will acquire Nanjing MeiRui Pharma for $70 million in cash. MeiRui specializes in urology and allergy therapies with products such as Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome. The deal also gives GSK a manufacturing facility in Nanjing City and a sales and marketing operation in China. GSK will purchase 90% of MeiRui from Pagoda Pharmaceuticals and 10% from the Swedish drug firm Allergon.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter